Foundation Medicine wins FDA OK for pan-tumor test as liquid biopsy market heats up

Foundation Medicine announced Wednesday that the FDA has approved its pan-tumor liquid biopsy test, which analyzes more than 300 genes and genomic signatures to help inform treatment decisions for all solid tumor cancers. This is the second agency nod the Cambridge, Massachusetts company has received for a pan-cancer blood assay.